323 related articles for article (PubMed ID: 33713769)
21. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.
Zhao ZT; Ji CM; Yu WJ; Meng L; Hawro T; Wei JF; Maurer M
J Allergy Clin Immunol; 2016 Jun; 137(6):1742-1750.e4. PubMed ID: 27040372
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
24. Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria.
Vonakis BM; Vasagar K; Gibbons SP; Gober L; Sterba PM; Chang H; Saini SS
J Allergy Clin Immunol; 2007 Feb; 119(2):441-8. PubMed ID: 17125820
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study.
Cakmak ME
Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494
[TBL] [Abstract][Full Text] [Related]
26. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria.
Asero R; Marzano AV; Ferrucci S; Lorini M; Carbonelli V; Cugno M
Clin Exp Immunol; 2020 Jun; 200(3):242-249. PubMed ID: 32115683
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
[TBL] [Abstract][Full Text] [Related]
28. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
[TBL] [Abstract][Full Text] [Related]
29. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
[TBL] [Abstract][Full Text] [Related]
30. Differentiation between control subjects and patients with chronic spontaneous urticaria based on the ability of anti-IgE autoantibodies (AAbs) to induce FcεRI crosslinking, as compared to anti-FcεRIα AAbs.
Izaki S; Toyoshima S; Endo T; Kanegae K; Nunomura S; Kashiwakura JI; Sasaki-Sakamoto T; Nakamura R; Akiyama H; Ra C; Hayama K; Terui T; Okayama Y
Allergol Int; 2019 Jul; 68(3):342-351. PubMed ID: 30803853
[TBL] [Abstract][Full Text] [Related]
31. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
Chang TW; Chen C; Lin CJ; Metz M; Church MK; Maurer M
J Allergy Clin Immunol; 2015 Feb; 135(2):337-42. PubMed ID: 24948369
[TBL] [Abstract][Full Text] [Related]
32. Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticaria.
Poddighe D; Vangelista L
Cell Immunol; 2020 Dec; 358():104215. PubMed ID: 33137647
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers of Autologous Whole Blood Injection Efficacy in Patients with Chronic Spontaneous Urticaria with Autoreactivity: A Preliminary Study.
Chen Q; Luo J; Yang X; Chen W; Liu W; Song Z
Int Arch Allergy Immunol; 2024; 185(2):190-195. PubMed ID: 37952519
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
35. Treatment of chronic autoimmune urticaria with omalizumab.
Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
[TBL] [Abstract][Full Text] [Related]
36. Lower IgA Levels in Chronic Spontaneous Urticaria Are Associated With Lower IgE Levels and Autoimmunity.
Sauer M; Scheffel J; Frischbutter S; Kolkhir P; Xiang YK; Siebenhaar F; Altrichter S; Maurer M; Metz M; Krause K
Front Immunol; 2021; 12():657211. PubMed ID: 34012441
[TBL] [Abstract][Full Text] [Related]
37. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
[TBL] [Abstract][Full Text] [Related]
38. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
39. Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
Asero R; Ferrucci SM; Calzari P; Consonni D; Cugno M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108654
[TBL] [Abstract][Full Text] [Related]
40. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.
Eckman JA; Sterba PM; Kelly D; Alexander V; Liu MC; Bochner BS; Macglashan DW; Saini SS
J Allergy Clin Immunol; 2010 Apr; 125(4):889-895.e7. PubMed ID: 19962744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
